

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known		
				Application Number	10/531,855	
				Filing Date	April 18, 2005	
				First Named Inventor	Berkel, Patrick	
				Art Unit	1633	
Examiner Name	Kelaginamane T. Hiriyanne					
Attorney Docket Number	089995-000000US					
Sheet	1	of	3			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	US-5,633,076		05-1997	DeBoer et al.	
	A2	US-7,067,713		06-2006	Nuijens et al.	
	A3	US-2005/0223416		10-2005	Nuijens et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	A4	EP	0586909	A2	03-16-1994	Behringwerke AG	Transl: Abstract Only	<input checked="" type="checkbox"/>
	A5	FR	2601034	A1	01-08-1988	Inst Nat Sante Rech Med; Pasteur Institut	Transl: Abstract Only	<input checked="" type="checkbox"/>
	A6	WO	01/57079	A2	08-09-2001	PHARMING INTELLECTUAL PROPERTY B.V.		<input type="checkbox"/>
	A7	WO	96/03051	A1	02-08-1996	Gene Pharming Europ BV...		<input type="checkbox"/>
	A8	WO	92/22320	A1	12-23-1992	Genentech Inc.		<input type="checkbox"/>
	A9	WO	91/06650	A1	05-16-1991	Cetus Corp		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	A10	AKITA, N., et al., "The effect of C 1 esterase inhibitor on ischemia: reperfusion injury in the rat brain," <u>No To Shinkei</u> , Vol. 53(7), pp. 641-644 (2001) [Article in Japanese] <i>English Abstract only</i> .			<input checked="" type="checkbox"/>
	A11	BORK, et al., "Long-Term Prophylaxis with C1-inhibitor (C1 INH) Concentrate in Patients with Recurrent Angioedema Caused by Hereditary and Acquired C1-Inhibitor Deficiency," <u>J. Allergy Clinical Immunology</u> , Vol. 83, pp. 677-682 (1989)			<input type="checkbox"/>
	A12	BOS, I.G.A., et al., "Recombinant human C1-inhibitor produced in <i>Pichia pastoris</i> has the same inhibitory capacity as plasma C1-inhibitor," <u>Biochimica et Biophysica Acta</u> , Vol. 1648, pp. 75-83 (2003)			<input type="checkbox"/>
Examiner Signature	/Kelaginamane Hiriyanne/			Date Considered	03/15/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/531,855
				Filing Date	April 18, 2005
				First Named Inventor	Berkel, Patrick
				Art Unit	1633
Examiner Name	Kelaginamane T. Hiriyanana				
Attorney Docket Number	089995-000000US				
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	A13	CARTER P. et al., <u>Euro J. Biochem.</u> 173:163, (1988)	<input type="checkbox"/>	
	A14	CHU, L. and D.K. Robinson, "Industrial choices for protein production by large-scale cell culture," <u>Current Opinion in Biotechnology</u> , Vol. 12, pp. 180-187 (2001)	<input type="checkbox"/>	
	A15	CICARDI, M. et al., <u>Immunobiol.</u> 199:366, (1998)	<input type="checkbox"/>	
	A16	DAVIS A.E., <u>Ann. Rev. Immunol.</u> 6:595-628 (1988)	<input type="checkbox"/>	
	A17	DE FILIPPI, F et al., <u>Transfusion</u> 38:307, (1998)	<input type="checkbox"/>	
	A18	ELDERING, E. et al., "Expression of functional human C1 inhibitor in COS cells," <u>J. Biol. Chem.</u> Vol. 263(24), pp. 11776-11779 (1988)	<input type="checkbox"/>	
	A19	HACK, C. et al., <u>LANCET</u> , 339:8789 378, (1992)	<input type="checkbox"/>	
	A20	HOUDEBINE, L.M., "Transgenic Animal Bioreactor," <u>Transgenic Res.</u> , Vol. 9 (4-5), pp. 305-320 (2000)	<input type="checkbox"/>	
	A21	KOLES, K., et al., "Influence of Lactation Parameters on the N-Glycosylation of Recombinant Human C1 Inhibitor Isolated from the Milk of Transgenic Rabbits," <u>Glycobiology</u> , Vol. 14(11), pp. 979-986 (2004)	<input type="checkbox"/>	
	A22	LAMARK, T., et al., "Expression of active human C1 inhibitor in serpin domain of <i>Escherichia coli</i> ," <u>Protein Expression and Purification</u> , Vol. 22, pp.349-358 (2001)	<input type="checkbox"/>	
	A23	MARASINI, B., et al., "Treatment of hereditary angioedema," <u>Klin Wochenschr.</u> , Vol. 56(16), pp. 819-823 (1978) [Article in German] <i>English Abstract only.</i>	<input checked="" type="checkbox"/>	
Examiner Signature	/Kelaginamane Hiriyanana/		Date Considered	03/15/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/531,855
				Filing Date	April 18, 2005
				First Named Inventor	Berkel, Patrick
				Art Unit	1633
Examiner Name	Kelaginamane T. Hiriyanne				
Attorney Docket Number	089995-000000US				
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	A24	RAI, M. and H. Padh, "Expression of systems for production of heterologous proteins," <u>Current Science</u> , Vol. 80(9,10), pp. 1121-1128 (2001)	<input type="checkbox"/>	
	A25	SCHAPIRA, M. et al., <u>Complement</u> 2:111 (1985)	<input type="checkbox"/>	
	A26	WURM, F.M., "Production of recombinant protein therapeutics in cultivated mammalian cells," <u>Nature Biotechnology</u> , Vol. 22(11), pp. 1393-1398 (2004)	<input type="checkbox"/>	
	A27	ZURLO J. et al. <u>Fertility and Sterility</u> 54:64, (1990)	<input type="checkbox"/>	

Examiner Signature	/Kelaginamane Hiriyanne/	Date Considered	03/15/2009
-----------------------	--------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.